Therefore, future research should explore incorporating this biomarker into routine testing, along with BRAF and MSI status, and evaluate their integration with other transcriptomic, microbiome, or microenvironmental indicators to optimize the clinical management of patients with BRAFV600E NSCLC. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.